BRISBANE, Calif., Sept. 24, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Andrew Powell has joined InterMune as Executive Vice President, General Counsel and Corporate Secretary.
Mr. Powell will be responsible for managing the company's legal affairs. He will report to Dan Welch, Chairman, Chief Executive Officer and President of InterMune.
Mr. Welch said, "Andrew brings experience in many areas that are key to InterMune's future as our Esbriet sales continue to grow globally, and we plan for anticipated approval and launch of Esbriet in the United States."Mr. Powell's experience spans two decades of leadership in the life sciences, most recently as Executive Vice President, General Counsel and Secretary at Cornerstone Therapeutics. Mr. Powell has practiced law for more than 25 years, principally in healthcare and biotechnology. He held positions of increasing responsibility for more than 15 years at the multi-national healthcare company Baxter, where he was instrumental in a series of transactions that established Baxter throughout Asia; Mr. Powell led the global law practice at Baxter Bioscience. Subsequently, he was part of the senior team that repositioned Collagenex Pharmaceuticals as a leader in dermatology. Mr. Powell then served as SVP and General Counsel at ImClone Systems, where he helped the company grow before playing a key role in a successful process that resulted in a sale to Eli Lilly. Mr. Powell holds a B.A. from the University of North Carolina at Chapel Hill and a J.D. from Stanford Law School. About InterMune InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet ® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com/. SOURCE InterMune, Inc.